[go: up one dir, main page]

RU2016129536A - Препараты на основе терпенов и каннабиноидов - Google Patents

Препараты на основе терпенов и каннабиноидов Download PDF

Info

Publication number
RU2016129536A
RU2016129536A RU2016129536A RU2016129536A RU2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A RU 2016129536 A RU2016129536 A RU 2016129536A
Authority
RU
Russia
Prior art keywords
terpene
pinene
group
myrcene
terpenes
Prior art date
Application number
RU2016129536A
Other languages
English (en)
Inventor
Марк ДОНСКИ
Роберт ВИННИЦКИ
Original Assignee
Фулл Спектрум Лабораториз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фулл Спектрум Лабораториз, Лтд. filed Critical Фулл Спектрум Лабораториз, Лтд.
Publication of RU2016129536A publication Critical patent/RU2016129536A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (27)

1. Препарат с водной липосомной формулой терпена включающей:
первичный терпен, отобранный из группы, включающей α-пинен, α-бизаболол, β-пипен, гуаен, гуайол, лимонен, мирцен и оцимен;
вторичный терпен;
третичный терпен,
где первичный терпен в формуле составляет 50% (процент от массы), вторичный терпен - примерно от 30% до 40% (процент от массы) и третичный терпен - примерно от 8% до 10% (процент от массы).
2. Препарат по п. 1, отличающийся тем, что в формулу дополнительно включены один или несколько каннабиноидов или их аналогов, при среднем диаметре липосомы в формуле в пределах 50-1000 нм.
3. Препарат по п. 2, отличающийся тем, что максимальная конечная концентрация каннабиноидов или их аналогов составляет примерно от 0,01 г/л до 100 г/л.
4. Препарат по п. 2, отличающийся тем, что один или несколько каннабиноидов или их аналогов выбраны из группы в составе каннабинола, каннадибиола, Δ9-тетрагидроканнабинола, Δ8-тетрагидроканнабинола, 11-гидрокси-тетрагидроканнабинола, 11-гидрокси-Δ9-тетрагидро каннабинола, левонантрадола, Δ11-тетрагидроканнабинола, тетрагидроканнабиварина, дронабинола, амандамида и набилона, и комбинации двух или более смесей.
5. Препарат по п. 2, отличающийся тем, что в формулу дополнительно включен стабилизатор, выбранный из группы в составе гуаровой смолы, гиалуроновой кислоты, целлюлозы, ксантановой смолы, поливинилового пирролидона (PVP), альгината, сульфат хондритина, полигаммаглютаминовой кислоты, желатина, хитизина, кукурузного крахмала и муки, в объеме примерно от 0,1% до 2% (процент от объема).
6. Препарат по п. 1, отличающийся тем, что первичный терпен представлен α-пиненом, вторичный терпен выбран из группы в составе мирцена, β-пинена и t-карофиллена, третичный терпен выбран из группы в составе β-пинена, t-карофиллена, α-бизаболола и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-бизаболола, гуаена, лимонена, оцимена, терпинолена, 3-карена, миерцена, гуайола, α-терпинеола и
линалоола.
7. Препарат по п. 1, отличающийся тем, что первичный терпен представлен α-бизабололом, а вторичный терпен t-карофилленом, третичный терпен выбран из группы в составе α-пинена и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-терпинеола, гуайола и линалоола.
8. Препарат по п. 1, отличающийся тем, что первичный терпен представлен β-пиненом, а вторичный терпен α-пиненом, третичный терпен выбран из группы в составе t-карофиллена и терпинолена, а в суспензию дополнительно входит незначительное количество мирцена.
9. Препарат по п. 1, отличающийся тем, что первичный терпен представлен гуайеном, а вторичный терпен t-карофилленом, третичный терпен выбран из группы в составе мирцена и α-гумулена, а в суспензию дополнительно входит незначительное количество α-пинена, α-бизаболола, β-пинена, лимонена, оцимена и терпинолена.
10. Препарат по п. 1, отличающийся тем, что первичный терпен представлен гуайолом, а вторичный терпен α-бизабололом, третичный терпен выбран из группы в составе t-карофиллена мирцена, а в суспензию дополнительно входит незначительное количество α-пинена, α-терпинеола, α-гумулена и терпинолена.
11. Препарат по п. 1, отличающийся тем, что первичный терпен представлен лимоненом, вторичный терпен выбран из группы в составе мирцена и t-карофиллена, третичный терпен выбран из группы в составе линалоола, мирцена, β-пинена и t-карофиллена, α-бизаболола и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-пинена, β-пинена, фенхола, гуайена, линалоола, оцимена и α-терпинеола.
12. Препарат по п. 1, отличающийся тем, что первичный терпен представлен мирценом, вторичный терпен выбран из группы в составе α-пинена, t-карофиллена, терпинолена, оцимена, лимонена и линалоола, третичный терпен выбран из группы в составе β-пинена, t-карофиллена, лимонена, оцимена и мирцена; α-пинена, бизаболола и мирцена, а в суспензию дополнительно входит незначительное количество одного или нескольких терпенов, выбранных из группы в составе α-гумулена, α-бизаболола, гуаена, лимонена, оцимена, 3-карена, β-пинена, α-пинена, миерцена, гуайола, α-терпинеола,
терпинолена и линалоола.
13. Метод приготовления стабильной липосомальной формулы, содержащей один или несколько терпенов, состоит из следующих операций:
(a) растворить один или несколько терпенов в этаноле для получения этанолового раствора терпенов;
(b) добавить фосфолипид в этаноловый раствор терпенов;
(c) произвести впрыск полученного при выполнении операции (b) раствора в дистиллированную воду для получения водно-спиртовой липосомальной формулы терпенов;
(d) извлечь этанол из водно-спиртовой липосомальной формулы терпенов для получения стабильной водной липосомальной формулы с одним или несколькими терпенами, где максимальная конечная концентрация терпенов в липосомальной формуле составляет примерно от 0,01 г/л до 100 г/л.
14. Метод по п. 13, отличающийся тем, что максимальная конечная концентрация терпенов в липосомальной формуле составляет примерно от 10 г/л до 70 г/л.
15. Метод по п. 13, отличающийся тем, что, при выполнении операции (а) дополнительно применяется растворение одного или нескольких каннабиноидов или аналогов каннабиноидов, выбранных из группы в составе каннабинола, каннабидиола, Δ9-тетрагидроканнабинола, Δ8-тетрагидроканнабинола, 11-гидрокси-тетрагидроканнабинола, 11-гидрокси-Δ9-тетрагидроканнабинола, левонантрадола, Δ11-тетрагидроканнабинола, тетрагидроканнабиварина, дронабинола, амандамида, набилона и их сочетаний.
16. Метод по п. 15, отличающийся тем, что средний диаметр липосомов составляет от 50 нм до 1000 нм, а максимальная конечная концентрация каннабиноидов или аналогов каннабиноидов в суспензии - примерно от 0,01 г/л до 100 г/л.
17. Препарат в виде водного раствора терпена и каннабиноида включает в себя первичный терпен, вторичный терпен и третичный терпен, а также один или несколько каннабиноидов или аналогов каннабиноидов, при общем содержании терпена и каннабиноида или терпена и аналога каннабиноида, равном 50 г/л.
RU2016129536A 2013-10-31 2014-10-31 Препараты на основе терпенов и каннабиноидов RU2016129536A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361898024P 2013-10-31 2013-10-31
US61/898,024 2013-10-31
PCT/IB2014/003156 WO2015068052A2 (en) 2013-10-31 2014-10-31 Terpene and cannabinoid formulations

Publications (1)

Publication Number Publication Date
RU2016129536A true RU2016129536A (ru) 2018-01-31

Family

ID=52811147

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016129536A RU2016129536A (ru) 2013-10-31 2014-10-31 Препараты на основе терпенов и каннабиноидов

Country Status (10)

Country Link
US (1) US20160279073A1 (ru)
EP (1) EP3062774A2 (ru)
JP (1) JP2016537412A (ru)
KR (1) KR20160094950A (ru)
CN (1) CN105916492A (ru)
AU (1) AU2014347807A1 (ru)
CA (1) CA2929280A1 (ru)
IL (1) IL245368A0 (ru)
RU (1) RU2016129536A (ru)
WO (1) WO2015068052A2 (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738268B2 (en) * 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US10595555B2 (en) * 2013-11-04 2020-03-24 Jason Wasserman Methods for creating concentrated plant material solutions
US20160037823A1 (en) * 2014-08-11 2016-02-11 Aari Ruben Medical therapy using cigarettes
CN113509499A (zh) 2014-10-21 2021-10-19 联合大麻公司 大麻提取物及其制备和使用方法
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
EP3229789A4 (en) * 2014-12-12 2018-08-08 Ojai Energetics PBC Microencapsulated cannabinoid compositions
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
HK1248564A1 (zh) 2015-03-02 2018-10-19 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
EP3268043A4 (en) * 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
WO2016147186A1 (en) * 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US11524042B2 (en) 2015-09-27 2022-12-13 Buzzelet Development And Technologies Ltd. Methods for the production of different cannabis product compositions
EP3368033A4 (en) 2015-10-31 2019-06-26 Canabuzz-Med THERAPEUTIC HONEY CANNABINOID COMPOSITION
US11590230B2 (en) 2015-12-07 2023-02-28 Elka Touitou Compositions of therapeutic substances, methods and uses thereof
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
CA3011185A1 (en) * 2016-01-20 2017-07-27 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
IL301006A (en) * 2016-03-16 2023-04-01 Buzzelet Development And Technologies Ltd Cannobinoid compounds are rich in terpenes
US10542770B2 (en) 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
AU2017250001B2 (en) * 2016-04-12 2017-12-14 Little Green Pharma Ltd Liposomal preparation and methods of treatment
EP3445179A4 (en) * 2016-04-19 2020-07-22 Canna-B Cure Ltd ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION ENRICHED IN CANNABIS
AU2017260706B2 (en) * 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
CA3022553C (en) * 2016-05-06 2023-02-21 Zeyead GHARIB The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2017214497A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
JP2019518760A (ja) * 2016-06-15 2019-07-04 オーハイ エナジェティクス ピービーシー 幹細胞療法を増強するための方法および組成物
JP7454332B2 (ja) * 2016-06-15 2024-03-22 オーハイ エナジェティクス ピービーシー 酸化ストレスを低減するための方法および組成物
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-emulsifying compositions of cannabinoids
US20190230976A1 (en) * 2016-07-16 2019-08-01 Connoisseur Holdings, Llc System and method of forming a terpene solution
KR20190035791A (ko) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US20180049994A1 (en) * 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
AU2017319320B2 (en) 2016-08-29 2023-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
US10092538B2 (en) * 2016-10-21 2018-10-09 Axim Biotechnologies, Inc. Suppositories comprising cannabinoids
US10857482B1 (en) * 2016-12-07 2020-12-08 Rien Havens Botanical super heated processing equipment
NZ755319A (en) 2016-12-16 2025-07-25 Flavorsense Dried flakes with active ingredients
US12414936B2 (en) 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
BR112019016489A2 (pt) * 2017-02-09 2020-04-07 Caamtech Llc composições e métodos compreendendo um derivado da psilocibina
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC PREPARATIONS
EP3589787A4 (en) * 2017-03-02 2021-01-06 Iiw Entourage Delivery Systems Ltd FLAVORED AND PERFUMED PAPER PRODUCTS
BR112019020554A2 (pt) * 2017-03-30 2020-04-28 Ojai Energetics Pbc métodos e composições para melhorar as condições de saúde
EP3644986A4 (en) * 2017-05-01 2021-01-06 MJ Wooly Corporation METHODOLOGY AND FORMULATION FOR CREATING A POWDER FROM AN ENCAPSULATED CANNABIS-BASED COMPONENT INCORPORATED IN A POLYMERIC MATRIX
WO2018217803A2 (en) 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
BR112019024911A2 (pt) * 2017-05-26 2020-09-01 Altum Pharmaceuticals Inc. entrega de canabinoide biphasix
US10058531B1 (en) * 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
US10206888B2 (en) 2017-06-06 2019-02-19 Cmg Partners, Inc. Cannabis-based therapeutic product for treatment of chronic pain
WO2018232448A1 (en) 2017-06-19 2018-12-27 Zelda Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
CA3068383A1 (en) * 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid product for women health
CN110996926A (zh) * 2017-07-20 2020-04-10 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于将亲脂性化合物递送进入和/或穿过皮肤的药物膜组合物
WO2019034936A2 (en) * 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd TERPENE ENRICHED CANNABINOID COMPOSITION AND PROCESSING METHOD
US11925652B2 (en) * 2017-08-13 2024-03-12 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
WO2019056123A1 (en) 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
WO2019057899A1 (en) * 2017-09-22 2019-03-28 Lipid Systems Sp. Z.O.O. AQUEOUS COMPOSITION COMPRISING AT LEAST ONE PHOSHOLIPID AND AT LEAST ONE TERPENE WITH ACIDICITY ACTIVITY AGAINST DEMODEX
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
WO2019075006A1 (en) * 2017-10-10 2019-04-18 La'au Pono TREATMENT OF BOTANICAL EXTRACT DRYED BY SPRAYING
CA3080434A1 (en) 2017-10-30 2019-05-09 Endocanna Health, Inc. Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations
NZ764977A (en) 2017-10-30 2023-01-27 Whistler Tech Corp Terpene enrichment methods and systems
WO2019100168A1 (en) * 2017-11-27 2019-05-31 Enrico BOUCHARD Method of preparing a cannabis based terpene beverage and beverage thereof
US20210212946A1 (en) * 2018-01-03 2021-07-15 Icdpharma Ltd. Solid self-emulsifying cannabinoid compositions
EP3735241A4 (en) * 2018-01-03 2021-08-18 ICDPharma Ltd TASTE-ENHANCED CANNABINOID SUBMICRONIC EMULSION SYRUP COMPOSITIONS
BR102018002843A2 (pt) 2018-02-09 2019-08-27 Prati Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
CA3096062A1 (en) 2018-04-03 2019-10-10 Pure Green, Llc Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2019199861A2 (en) 2018-04-09 2019-10-17 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019220324A2 (en) * 2018-05-14 2019-11-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid compositions and uses thereof in the treatment of infectious conditions
CA3100947A1 (en) * 2018-05-22 2019-11-28 Gbs Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation
US11252985B1 (en) * 2018-05-31 2022-02-22 Cannasphere Biotech, LLC. Dietary supplement compositions including cannabidiol formulations having enhanced bioavailability with sustained time release and enhanced organoleptics, and methods of making same
WO2019237200A1 (en) * 2018-06-12 2019-12-19 Paige Growth Technologies Inc. Precision agriculture system and related methods
US10946307B2 (en) * 2018-07-12 2021-03-16 Bright Green Corporation Extraction of cannabinoids, curcuminoids and ginsenosides
US10946308B2 (en) * 2018-07-12 2021-03-16 Bright Green Corporation Enzymatic method for extraction and purification of phytocannabinoids
US10751299B2 (en) * 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
US11235013B2 (en) 2018-09-04 2022-02-01 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US20200078427A1 (en) 2018-09-06 2020-03-12 NuVessl, Inc. Cannabis Sativa Derived Formulation for Transmucosal and Transdermal Delivery
MX2021004138A (es) * 2018-10-10 2021-08-05 Tilray Inc Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
WO2020092987A1 (en) * 2018-11-01 2020-05-07 Molecular Infusions, Llc Polymer-based oral cannabinoid and/or terpene formulations
JP7326445B2 (ja) * 2018-12-11 2023-08-15 ディスラプション・ラブズ・インコーポレイテッド 治療剤の送達のための組成物並びにその使用及び製造方法
EP3897684A4 (en) * 2018-12-21 2022-10-12 Botaneco Inc. CANNABINOID FORMULATIONS AND METHODS OF PREPARING THEM
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
WO2020136627A1 (en) * 2018-12-29 2020-07-02 Buzzelet Development And Technologies Ltd. Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
CA3127092A1 (en) * 2019-01-17 2020-07-23 Michaela MULHARE Solid micellar compositions of cannabinoid acids
US12201724B2 (en) 2019-01-24 2025-01-21 CannaClear Inc. Lecithin vesicles for oral delivery
US12324800B2 (en) 2019-01-24 2025-06-10 CannaClear Inc. Lecithin vesicles
US11154502B2 (en) 2019-01-24 2021-10-26 CannaClear Inc. Lecithin vesicles for oral delivery
CA3038349C (en) * 2019-01-31 2021-04-13 Nam Hai LAI Process for producing a nano-cbd liposome system
WO2020161715A1 (en) * 2019-02-07 2020-08-13 Cannasoul Analytics Ltd. Cannabinoid containing composition, methods of preparation and use thereof
WO2020163775A1 (en) * 2019-02-08 2020-08-13 Srin Therapeutics, Inc. Cannabinoid compositions and methods of use thereof for immune modulation, immune protection, and treatment of cancer
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
EP3955747A4 (en) * 2019-04-15 2023-02-01 Metagenics, Inc. NEW HEMP AND PEA FORMULATION AND ITS USE
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
CN111838746B (zh) * 2019-04-30 2022-04-05 云南汉盟制药有限公司 一种香烟爆珠及其制备方法和香烟
KR20220035043A (ko) * 2019-05-23 2022-03-21 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 방사선 치료제 마이크로스피어
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
LU102486B1 (en) * 2019-06-03 2021-06-15 Fresh Cut Dev Llc Cannabidiol nanocrystal compositions
KR102478632B1 (ko) * 2019-06-18 2022-12-19 바이오메디칼쓰리디프린팅 주식회사 Ｃｂｄ를 포함하는 ３ｄ 객체 및 그의 프린팅 운영 시스템
JP7398820B2 (ja) * 2019-06-18 2023-12-15 バイオ メディカル ３ディー プリンティング カンパニー リミテッド Ｃｂｄを含む３ｄ客体及びそのプリンティング運営システム
US11622956B1 (en) * 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
CA3142985A1 (en) * 2019-07-03 2021-01-07 Vertosa Inc. Infusion of emulsified hydrophobic active ingredients into high polyphenolic beverages
US20210023005A1 (en) * 2019-07-26 2021-01-28 Landsteiner Scientific S.A. De C.V. Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications
IL268457B (en) 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
CA3156487A1 (en) * 2019-10-03 2021-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. LIPOSOMAL CANNABINOIDS AND ASSOCIATED USES
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
AU2020377914A1 (en) * 2019-11-08 2022-06-02 Vella Bioscience, Inc. Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
MX2022011176A (es) 2020-03-09 2023-02-16 Northeast Kind Assets Llc Proceso para preparar un aceite de cáñamo de espectro completo soluble en agua.
WO2021179087A1 (en) * 2020-03-11 2021-09-16 Hexo Operations Inc. Terpene-enhanced compositions and uses thereof
WO2021179088A1 (en) * 2020-03-13 2021-09-16 Hexo Operations Inc. Terpene-enhanced compositions and uses thereof
CA3183163A1 (en) * 2020-05-18 2021-11-25 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
FR3110427B1 (fr) * 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
CN113925896A (zh) * 2020-06-29 2022-01-14 汉义生物科技（北京）有限公司 一种含大麻提取物的药物组合物、制剂及其应用
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
CN111643377B (zh) * 2020-07-23 2023-08-11 中国热带农业科学院南亚热带作物研究所 一种汉麻油纳米微胶囊及其制备方法和应用
WO2022027053A1 (en) * 2020-07-28 2022-02-03 Wsmef, Llc Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
EP4188363A4 (en) 2020-07-28 2024-10-16 Wsmef, Llc FULL-SPECTRUM HEMP OIL MICELLE PREPARATIONS FOR THE TREATMENT OF TYPE II DIABETES, REDUCING INFLAMMATION DURING COVID-19 AND IMPROVING SLEEP QUALITY
US20220054446A1 (en) * 2020-08-18 2022-02-24 Yvette Rose Webb Targeted treatment with a topical cream of cannabinoids, terpenes, and essential oils
US11731950B2 (en) * 2020-09-07 2023-08-22 Shuang Xie Mass production and application of Δ 8 THC
IL303034A (en) * 2020-11-06 2023-07-01 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology
WO2022126112A1 (en) * 2020-12-08 2022-06-16 Dt Ip Holdings I, Llc Formulations containing cannabinoids
CA3204862A1 (en) 2020-12-09 2022-06-16 I+Med S. Coop. Composition comprising sea water and cannabinoid loaded submicroparticles for pharmaceutical, nutraceutical and cosmetic applications
CN112472661A (zh) * 2020-12-11 2021-03-12 云南苏旺润生物医药有限公司 一种大麻二酚按摩油组合物及其制备方法和应用
CA3102947A1 (en) * 2020-12-18 2022-06-18 Skymount Medical Us Inc. Nutraceuticals useful in the treatment of coronavirus diseases
WO2022137215A1 (en) * 2020-12-24 2022-06-30 Czupiel Petro Pawlo Safe-to-ingest cationic microemulsions and nanoemulsions containing lipophilic components
WO2022140849A1 (en) * 2021-01-04 2022-07-07 Hexo Operations Inc. Cannabinoid compositions with taste-barrier properties
WO2022165165A1 (en) * 2021-01-29 2022-08-04 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
US12011470B2 (en) 2021-07-28 2024-06-18 Clint Sorensen Micelle preparations of full-spectrum hemp oil
WO2023060323A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Terpene-containing formulations and use thereof
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
US20230346810A1 (en) * 2022-04-29 2023-11-02 Abstrax Tech Inc. Endogenous stabilization of cannabinoids
WO2024057304A1 (en) * 2022-09-12 2024-03-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for dermal/transdermal delivery and cosmetic use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4424797A (en) * 1996-09-18 1998-04-14 Dragoco Inc. Liposome encapsulated active agent dry powder composition
AU2002360517A1 (en) * 2001-12-07 2003-06-23 Ximed Group Plc Respiratory infection prevention and treatment with terpene-containing compositions
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
AU2007281918A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
EP2201942A1 (de) * 2008-12-23 2010-06-30 Intendis GmbH Zusammensetzung mit Hanföl für die Behandlung topischer Erkrankungen
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol

Also Published As

Publication number Publication date
EP3062774A2 (en) 2016-09-07
CN105916492A (zh) 2016-08-31
CA2929280A1 (en) 2015-05-14
AU2014347807A1 (en) 2016-05-26
US20160279073A1 (en) 2016-09-29
KR20160094950A (ko) 2016-08-10
JP2016537412A (ja) 2016-12-01
WO2015068052A3 (en) 2015-09-03
WO2015068052A2 (en) 2015-05-14
IL245368A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
RU2016129536A (ru) Препараты на основе терпенов и каннабиноидов
JP2016537412A5 (ru)
PE20190318A1 (es) Composicion administrable oralmente
Brand et al. The water-soluble components of the essential oil of Melaleuca alternifolia (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro
AU2014332488B2 (en) Methods and compositions for treating and preventing signs or symptoms of eye disease
Bhosale et al. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation
de Freitas et al. Influence of aqueous crude extracts of medicinal plants on the osmotic stability of human erythrocytes
MX2014013884A (es) Sistema de vehiculo oftalmologico para farmacos, kit oftalmologico y tambien uso de una composicion oftalmologica.
EP2635266A1 (de) Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator
BR112016029544A2 (pt) partículas de sílica porosa, método de fabricação e produto cosmético contendo as mesmas
CN103735532A (zh) 叶黄素酯微胶囊及其制备方法
BR112021024836A2 (pt) Artigo para uso em um sistema de provisão de aerossol não combustível, sistema e método de fabricação de um artigo para uso em um sistema de provisão de aerossol não combustível
CN103404537B (zh) 一种桂枝提取物的制备方法及其制备的桂枝提取物和用途
IL292514A (en) A dosage form for vaporization and smoking
AR089962A1 (es) Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso
CL2012000515A1 (es) Sustancia colorante dispersable en agua que comprende carbo vegetabilis y por lo menos 1% de un derivado de octenil succinato de almidón como agente dispersante; método de preparación de la sustancia colorante; su uso; y producto comestible y farmacéutico que lo contienen.
CN102934704A (zh) 抗氧化食用油
AU2015351930B2 (en) Biologically-active tomato composition having reduced amount of lycopene
CN109321991A (zh) 一种多功能复合添加剂、具有抗菌、防螨、生发负离子功能的粘胶纤维及其制备方法
CN103815545A (zh) 角鲨烯与茶多酚组合物多囊脂质体的制备方法及其降基减害应用
Namoune et al. Antioxidant and anti-inflammatory activities of organic and aqueous extracts of Northeast Algerian Marrubium vulgare
CN106490680A (zh) 一种橄榄多酚纳米脂质体卷烟滤嘴材料及其应用
CN103859588A (zh) 角鲨烯与虾青素组合物多囊脂质体的制备及其降基减害
Hagiwara et al. ETS-GS, a new antioxidant, ameliorates renal ischemia-reperfusion injury in a rodent model
CN103767070B (zh) 角鲨烯与虾青素组合物液态前体脂质体的制备方法及其降基减害应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190404